Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of RYALTRIS® (Olopatadine Hydrochloride / Mometasone Furoate Monohydrate) Nasal Spray on Patients' Reported Outcomes

NCT05129306 is registered in ClinicalTrials.gov with Community and Patient Preference Research Pty Ltd as lead sponsor.

NCT NCT05129306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05129306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of RYALTRIS® (Olopatadine Hydrochloride / Mometasone Furoate Monohydrate) Nasal Spray on Patients' Reported Outcomes
Lead sponsor
Community and Patient Preference Research Pty Ltd
Phase
Observational
Overall status
Withdrawn
Start date
November 17, 2021
Completion date
March 14, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis